Abstract
Bone marrow, peripheral blood and cord blood are all sources of hematopoietic stem cells for allogeneic transplants. These sources differ in regard to collection methods, cellular content and transplant outcomes. In the related setting, use of peripheral blood stem cells, when compared to bone marrow, results in faster engraftment and may confer a survival benefit in advanced disease but also may lead to an increase in chronic graft-versus-host-disease. While cord blood stem cells are the simplest to collect and allow the greatest flexibility in HLA matching, they contain the lowest stem cell dose leading to the slowest engraftment. In this review, we discuss the advantages and disadvantages of these different stem cell sources as well as areas for further research.
Keywords: Bone marrow transplant, hematopoietic stem cell transplant, cord blood transplant, peripheral blood stem cell transplant
Current Stem Cell Research & Therapy
Title: Hematopoietic Stem Cells: Source Matters
Volume: 3 Issue: 4
Author(s): Richard L. Haspel and Kenneth B. Miller
Affiliation:
Keywords: Bone marrow transplant, hematopoietic stem cell transplant, cord blood transplant, peripheral blood stem cell transplant
Abstract: Bone marrow, peripheral blood and cord blood are all sources of hematopoietic stem cells for allogeneic transplants. These sources differ in regard to collection methods, cellular content and transplant outcomes. In the related setting, use of peripheral blood stem cells, when compared to bone marrow, results in faster engraftment and may confer a survival benefit in advanced disease but also may lead to an increase in chronic graft-versus-host-disease. While cord blood stem cells are the simplest to collect and allow the greatest flexibility in HLA matching, they contain the lowest stem cell dose leading to the slowest engraftment. In this review, we discuss the advantages and disadvantages of these different stem cell sources as well as areas for further research.
Export Options
About this article
Cite this article as:
Haspel L. Richard and Miller B. Kenneth, Hematopoietic Stem Cells: Source Matters, Current Stem Cell Research & Therapy 2008; 3 (4) . https://dx.doi.org/10.2174/157488808786734033
DOI https://dx.doi.org/10.2174/157488808786734033 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
N6-Isopentenyladenosine and its Analogue N6-Benzyladenosine Induce Cell Cycle Arrest and Apoptosis in Bladder Carcinoma T24 Cells
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights
MicroRNA Sumoylation in Cellular Senescence and Aging
Current Molecular Medicine Distinct Epigenetic Reprogramming, Mitochondrial Patterns, Cellular Morphology, and Cytotoxicity after Bee Venom Treatment
Recent Patents on Anti-Cancer Drug Discovery Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics Multiple Metamorphoses of CD38 from Prognostic Marker to Disease Modifier to Therapeutic Target in Chronic Lymphocytic Leukemia
Current Topics in Medicinal Chemistry Naturally Occuring Pyrrolo[1,4]benzodiazepines in Bacteria
Mini-Reviews in Organic Chemistry Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy Cryopreservation of Ovarian Tissue: State of the Art in 2007
Current Women`s Health Reviews E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Ribonucleotide Reductase as One Important Target of [Tris(1,10- phenanthroline)lanthanum(III)] Trithiocyanate (KP772)
Current Cancer Drug Targets Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1<sup>®</sup> can Overcome Drug Resistance in Osteosarcoma
Current Cancer Drug Targets Approaches to Quantification of RNA Targets by PCR Based Techniques
Current Genomics A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry